Literature DB >> 28511252

Diagnosis and Management of Parkinson's Disease.

Arjun Tarakad1, Joseph Jankovic1.   

Abstract

Despite numerous efforts to identify specific and sensitive biomarkers, the diagnosis of Parkinson's disease (PD) is still based on clinical criteria that include the presence of a combination of cardinal motor features (tremor, rigidity, bradykinesia, and postural instability), other motor features (including freezing of gait and abnormal postures), and numerous nonmotor features. In addition, the presence of atypical features may suggest an alternative diagnosis. Levodopa therapy remains the gold standard in the management of motor features of PD. New formulations of levodopa and novel delivery systems are currently being evaluated and gradually introduced in clinical practice in an attempt to prevent or treat levodopa-related motor complications. Dopamine agonists also play an important role as monotherapy in mild or adjunctive therapy in moderately advanced disease. As the disease progresses and patients develop complications from levodopa therapy, specifically motor fluctuations and dyskinesias, deep brain stimulation becomes an alternative therapeutic option. Clinical trials of experimental therapeutics are currently fueling the PD therapeutic pipeline. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28511252     DOI: 10.1055/s-0037-1601888

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  22 in total

1.  Chronic exposure to methylmercury induces puncta formation in cephalic dopaminergic neurons in Caenorhabditis elegans.

Authors:  Tao Ke; Aristidis Tsatsakis; Abel Santamaría; Félix Alexandre Antunes Soare; Alexey A Tinkov; Anca Oana Docea; Anatoly Skalny; Aaron B Bowman; Michael Aschner
Journal:  Neurotoxicology       Date:  2020-01-11       Impact factor: 4.294

2.  Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.

Authors:  Joseph Jankovic; Ira Goodman; Beth Safirstein; Tonya K Marmon; Dale B Schenk; Martin Koller; Wagner Zago; Daniel K Ness; Sue G Griffith; Michael Grundman; Jay Soto; Susanne Ostrowitzki; Frank G Boess; Meret Martin-Facklam; Joseph F Quinn; Stuart H Isaacson; Omid Omidvar; Aaron Ellenbogen; Gene G Kinney
Journal:  JAMA Neurol       Date:  2018-10-01       Impact factor: 18.302

3.  Downregulation of lncRNA BACE1-AS improves dopamine-dependent oxidative stress in rats with Parkinson's disease by upregulating microRNA-34b-5p and downregulating BACE1.

Authors:  Yanhong Li; Jian Fang; Zhanye Zhou; Qiyu Zhou; Shibin Sun; Zhikai Jin; Ziming Xi; Jianshe Wei
Journal:  Cell Cycle       Date:  2020-04-19       Impact factor: 4.534

4.  circ-Pank1 promotes dopaminergic neuron neurodegeneration through modulating miR-7a-5p/α-syn pathway in Parkinson's disease.

Authors:  Qing Liu; Qiyao Li; Runjiao Zhang; Hongfang Wang; Yibo Li; Ziyu Liu; Wenmeng Xie; Dandan Geng; Lei Wang
Journal:  Cell Death Dis       Date:  2022-05-19       Impact factor: 9.685

Review 5.  Pimavanserin in the Treatment of Parkinson's Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials.

Authors:  Zeeshan Mansuri; Abhishek Reddy; Ramu Vadukapuram; Chintan Trivedi; Amy Amara
Journal:  Innov Clin Neurosci       Date:  2022 Jan-Mar

Review 6.  Oxidative stress factors in Parkinson's disease.

Authors:  Jolanta Dorszewska; Marta Kowalska; Michał Prendecki; Thomas Piekut; Joanna Kozłowska; Wojciech Kozubski
Journal:  Neural Regen Res       Date:  2021-07       Impact factor: 5.135

7.  Therapies for Genetic Forms of Parkinson's Disease: Systematic Literature Review.

Authors:  Laura Over; Norbert Brüggemann; Katja Lohmann
Journal:  J Neuromuscul Dis       Date:  2021

Review 8.  Progress toward an integrated understanding of Parkinson's disease.

Authors:  Maxime W C Rousseaux; Joshua M Shulman; Joseph Jankovic
Journal:  F1000Res       Date:  2017-07-12

9.  Serum fractalkine and 3-nitrotyrosine levels correlate with disease severity in Parkinson's disease: a pilot study.

Authors:  Manjeet Gupta; Vimal Kumar Paliwal; G Nagesh Babu
Journal:  Metab Brain Dis       Date:  2021-08-03       Impact factor: 3.584

10.  Tocotrienols Ameliorate Neurodegeneration and Motor Deficits in the 6-OHDA-Induced Rat Model of Parkinsonism: Behavioural and Immunohistochemistry Analysis.

Authors:  Mangala Kumari; Premdass Ramdas; Ammu Kutty Radhakrishnan; Methil Kannan Kutty; Nagaraja Haleagrahara
Journal:  Nutrients       Date:  2021-05-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.